These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23895805)

  • 21. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department.
    Stiell IG; Macle L;
    Can J Cardiol; 2011; 27(1):38-46. PubMed ID: 21329861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atrial fibrillation: pharmacological therapy.
    Patel C; Salahuddin M; Jones A; Patel A; Yan GX; Kowey PR
    Curr Probl Cardiol; 2011 Mar; 36(3):87-120. PubMed ID: 21392636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurologic Complications of Chronic Kidney Disease.
    Vellanki K; Bansal VK
    Curr Neurol Neurosci Rep; 2015 Aug; 15(8):50. PubMed ID: 26081561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.
    Kirchhof P; Breithardt G; Camm AJ; Crijns HJ; Kuck KH; Vardas P; Wegscheider K
    Am Heart J; 2013 Sep; 166(3):442-8. PubMed ID: 24016492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atrial fibrillation and chronic kidney disease conundrum: an update.
    Tapoi L; Ureche C; Sascau R; Badarau S; Covic A
    J Nephrol; 2019 Dec; 32(6):909-917. PubMed ID: 31321745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.
    Skanes AC; Healey JS; Cairns JA; Dorian P; Gillis AM; McMurtry MS; Mitchell LB; Verma A; Nattel S;
    Can J Cardiol; 2012; 28(2):125-36. PubMed ID: 22433576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stroke features and management in patients with chronic kidney disease.
    Kamouchi M
    Contrib Nephrol; 2013; 179():92-9. PubMed ID: 23652452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Quandary of Oral Anticoagulation in Patients With Atrial Fibrillation and Chronic Kidney Disease.
    Schwartzenberg S; Lev EI; Sagie A; Korzets A; Kornowski R
    Am J Cardiol; 2016 Feb; 117(3):477-82. PubMed ID: 26721651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-thrombotic therapy for atrial fibrillation in patients with chronic kidney disease: Current views.
    Ghadban R; Flaker G; Katta N; Alpert MA
    Hemodial Int; 2017 Oct; 21 Suppl 2():S47-S56. PubMed ID: 29064182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of patients with atrial fibrillation and chronic kidney disease in light of the latest guidelines.
    Młodawska E; Tomaszuk-Kazberuk A; Łopatowska P; Musiał WJ; Małyszko J
    Pol Arch Med Wewn; 2016 May; 126(5):353-62. PubMed ID: 27243343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticoagulants, renal failure and atrial fibrillation.
    Genovesi S; Santoro A
    Expert Opin Drug Saf; 2013 Jan; 12(1):1-3. PubMed ID: 23163428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there association between changes in eGFR value and the risk of permanent type of atrial fibrillation? Analysis of valvular and non-valvular atrial fibrillation population.
    Mlodawska E; Tomaszuk-Kazberuk A; Lopatowska P; Bachorzewska-Gajewska H; Malyszko J; Dobrzycki S; Musial WJ
    Kidney Blood Press Res; 2014; 39(6):600-8. PubMed ID: 25531163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease.
    Stoica MC; Gáll Z; Gliga ML; Căldăraru CD; Székely O
    Medicina (Kaunas); 2021 Apr; 57(5):. PubMed ID: 33925501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal trends in medication use and outcomes in atrial fibrillation.
    Pilote L; Eisenberg MJ; Essebag V; Tu JV; Humphries KH; Leung Yinko SS; Behlouli H; Guo H; Jackevicius CA
    Can J Cardiol; 2013 Oct; 29(10):1241-8. PubMed ID: 23313007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atrial Fibrillation and Anticoagulant Treatment in End-Stage Renal Disease Patients: Where Do We Stand?
    Di Lullo L; Mariani MV; Ronco C; Bellasi A; Lavalle C; Chimenti C; Paoletti E; Ravera M; Zanella M
    Cardiorenal Med; 2022; 12(4):131-140. PubMed ID: 35671744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical review: clinical management of atrial fibrillation - rate control versus rhythm control.
    Lim HS; Hamaad A; Lip GY
    Crit Care; 2004 Aug; 8(4):271-9. PubMed ID: 15312210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atrial Fibrillation in Patients with Chronic Kidney Disease.
    Kotalczyk A; Ding WY; Wong CF; Rao A; Gupta D; Lip GYH
    Cardiol Clin; 2021 Aug; 39(3):435-446. PubMed ID: 34247756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atrial fibrillation and heart failure: natural history and pharmacological treatment.
    Savelieva I; John Camm A
    Europace; 2004 Sep; 5 Suppl 1():S5-19. PubMed ID: 15450275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.